Actively Recruiting
Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies
Led by Duke University · Updated on 2025-09-02
50
Participants Needed
1
Research Sites
231 weeks
Total Duration
On this page
Sponsors
D
Duke University
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistance in CAR T therapy.
CONDITIONS
Official Title
Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and provide signed informed consent that meets Institutional Review Board guidelines
- Confirmed diagnosis of hematologic malignancy
- Will be undergoing CAR T therapy with a commercial CAR T product
- Patients receiving CAR T therapy under a clinical trial protocol may also join if approved by the trial sponsor and investigator
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Duke University
Durham, North Carolina, United States, 27710
Actively Recruiting
Research Team
Q
Quinna Lawson
CONTACT
P
Peggy Alton
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here